Our results are consistent with other reports that found these mutations to be frequent in metastatic tumors, as the ESR1 mutation is often an acquired mutation during or after the treatment with aromatase inhibitors, and associated with a worse prognosis [32,33]. The gene discussed is CYP19A1; the disease is metastatic neoplasm.